Taxotere New Indication - Gastric Cancer Treatment Registration Trial
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To detect a statistically significant increase in time to progression (TTP) of disease for
the test group (Taxotere® [Docetaxel] combined with cisplatin and 5-fluorouracil [TCF])
relative to the control group (Cisplatin combined with 5-fluorouracil[CF])
Secondary objectives:
- To detect a statistically significant increase in overall survival (OS) for the test
group relative to the control group.
- To compare response rate (RR), time to treatment failure (TTF), duration of responses,
safety profiles, quality of life (QOL), and disease-related symptoms.